-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 18th, Jingxin Pharmaceutical announced that its wholly-owned subsidiary, Shangyu Jingxin, received the European Pharmacopoeia Certificate of Applicability for Levofloxacin API issued by the European Medicines Quality Administration
.
Levofloxacin is one of the quinolone drugs with broad-spectrum antibacterial effect.
It is suitable for respiratory infections, urinary system infections, reproductive system infections, skin and soft tissue infections, intestinal infections and other infections caused by sensitive bacteria
.
According to statistics, the global use of levofloxacin API will be about 718 tons in 2020, of which about 93 tons will be used in the European market
.
(Data comes from NEWPORT)